Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Key support ⢠Resistance overhead Support Level: $22.00-$22.20 Resistance Level: $23.50-$24.40 IMNM remains constructive over the last month, but momentum has faded and the stock is correcting below $24.39 resistance with $22.00-$22.20 as near-term support.
Sentiment & News
Key News Insights: ⢠FDA NDA Acceptance ⢠IM-3050 Trial Start ⢠Insider Selling Immunome's July headlines were driven by FDA acceptance of varegacestat's NDA and first IM-3050 patient dosing, offset by insider and institutional selling that may add volatility around the review timeline.
AI Summary
IMNM has shifted from a speculative oncology name to a near-term FDA catalyst story on varegacestat, but with the stock now hinging on one approval decision while the rest of the pipeline remains early-stage and cash burn/dilution persist, investors should treat any upside as execution-dependent rather than diversified.
Description
Immunome, Inc. is a biopharmaceutical firm that discovers and develops monoclonal antibody therapeutics for oncology and infectious diseases. Its lead oncology candidate, IMM-ONC-01, targets the IL-38 tumor-derived immune checkpoint implicated in tumor immune evasion, and the company also maintains an antibody cocktail program for SARS-CoV-2. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | IMNM | Immunome, Inc. | Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity. | Closed | +12.9% |